<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646954</url>
  </required_header>
  <id_info>
    <org_study_id>METHY3</org_study_id>
    <nct_id>NCT04646954</nct_id>
  </id_info>
  <brief_title>DNA Methylation Testing for the Screening of Uterine Cervical Lesion</brief_title>
  <official_title>DNA Methylation Testing for the Screening of Uterine Cervical Lesion: A Multicenter, Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In our published work, host DNA methylation testing has been proved to be sensitive and&#xD;
      specific to cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+). Its&#xD;
      screening effects are independent of high-risk human papillomavirus (hrHPV) status. Based on&#xD;
      the results of training and validation sets of our previous work, we perform this&#xD;
      multicenter, prospective cohort study in unselected participants asking for cervical cancer&#xD;
      screening in a hospital-based community. All eligible participants accept DNA methylation&#xD;
      testing, with cytology and/or hrHPV assay. The primary endpoint is the diagnostic accuracy of&#xD;
      DNA methylation compared with cytology and/or hrHPV status based on histology results. The&#xD;
      accuracy analysis includes sensitivity, specificity, negative predictive value and positive&#xD;
      predictive value.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All eligible participants accept DNA methylation testing, with cytology and/or hrHPV assay in a hospital-based communityã€‚</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>Two years</time_frame>
    <description>The accuracy analysis includes sensitivity, specificity, negative predictive value and positive predictive value.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <condition>DNA Methylation</condition>
  <condition>High-risk Human Papillomavirus</condition>
  <condition>Cytology</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible participants are included in the study group</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Host DNA methylation testing</intervention_name>
    <description>Host EPB41L3, JAM3 and PAX1 methylation testing by cytology sample</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cervical cytology and/or high-risk human papillomavirus assays</intervention_name>
    <description>Cervical cytology and/or high-risk human papillomavirus assays</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 21 years or older&#xD;
&#xD;
          -  Signed an approved informed consents&#xD;
&#xD;
          -  Feasible to be followed up&#xD;
&#xD;
          -  Available residual cytology samples for methylation analysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Without history of cervical disease, including cervical intraepithelial neoplasia&#xD;
             (CIN) 2 or more severe lesions (CIN2+)&#xD;
&#xD;
          -  No requirement of cervical cancer screening of cytology or high-risk human&#xD;
             papillomavirus&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

